{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:41:37Z","timestamp":1759405297721,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vaccine.2022.08.001","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T06:19:45Z","timestamp":1665641985000},"page":"6785-6794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase II, single-center, randomized, double-blind, parallel control clinical study evaluating the immunogenicity and safety of a two-dose schedule of serogroups ACYW meningococcal polysaccharide conjugate vaccine"],"prefix":"10.1016","volume":"40","author":[{"given":"Yi","family":"Mo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingkai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaojun","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.vaccine.2022.08.001_b0005","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1016\/j.vaccine.2013.04.003","article-title":"An overview of meningococcal disease in India: knowledge gaps and potential solutions","volume":"31","author":"John","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.001_b0010","doi-asserted-by":"crossref","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2022.08.001_b0015","unstructured":"Meningitis in Chad, Niger and Nigeria: 2009 epidemic season. Wkly Epidemiol Rec 2010 Feb 19;85(8):47-63. https:\/\/pubmed.ncbi.nlm.nih.gov\/20210043\/."},{"key":"10.1016\/j.vaccine.2022.08.001_b0020","doi-asserted-by":"crossref","unstructured":"Schwartz B, Moore PS, Broome CV. Global epidemiology of meningococcal disease. Clin Microbiol Rev 1989 Apr;2 Suppl(Suppl):S118-24. https:\/\/doi.org\/10.1128\/CMR.2.Suppl.S118.","DOI":"10.1128\/CMR.2.Suppl.S118"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.001_b0025","first-page":"241","article-title":"Serogroup distribution of meningococcal meningitis in China, 2015\u20132019","volume":"26","author":"Li","year":"2020","journal-title":"Zhongguo Yi Miao He Mian Yi"},{"issue":"7","key":"10.1016\/j.vaccine.2022.08.001_b0030","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/21645515.2020.1857201","article-title":"Meningococcal vaccines in China","volume":"17","author":"Xu","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.08.001_b0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mib.2014.11.006","article-title":"Neisseria meningitidis: pathogenesis and immunity","volume":"23","author":"Pizza","year":"2015","journal-title":"Curr Opin Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.001_b0040","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4161\/viru.26515","article-title":"Meningococcal disease and the complement system","volume":"5","author":"Lewis","year":"2014","journal-title":"Virulence"},{"key":"10.1016\/j.vaccine.2022.08.001_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","article-title":"Neisseria meningitidis: biology, microbiology, and epidemiology","volume":"799","author":"Rouphael","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"30 Suppl 2","key":"10.1016\/j.vaccine.2022.08.001_b0050","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.001_b0055","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3201\/eid1904.111799","article-title":"Description and nomenclature of Neisseria meningitidis capsule locus","volume":"19","author":"Harrison","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.001_b0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1128\/jb.146.1.69-78.1981","article-title":"Five structural classes of major outer membrane proteins in Neisseria meningitidis","volume":"146","author":"Tsai","year":"1981","journal-title":"J Bacteriol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.08.001_b0065","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/iai.55.7.1652-1656.1987","article-title":"Immunotype epitopes of Neisseria meningitidis lipooligosaccharide types 1 through 8","volume":"55","author":"Tsai","year":"1987","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.001_b0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1073\/pnas.94.1.271","article-title":"Capsule switching of Neisseria meningitidis","volume":"94","author":"Swartley","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2022.08.001_b0075","doi-asserted-by":"crossref","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969 Jun 1;129(6):1307-26. https:\/\/doi.org\/10.1084\/jem.129.6.1307.","DOI":"10.1084\/jem.129.6.1307"},{"issue":"9","key":"10.1016\/j.vaccine.2022.08.001_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2022.08.001_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2011\/846756","article-title":"Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience","volume":"2011","author":"Miller","year":"2011","journal-title":"Adv Prev Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.001_b0090","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1586\/erv.12.32","article-title":"MenACWY-TT vaccine for active immunization against invasive meningococcal disease","volume":"11","author":"Papaevangelou","year":"2012","journal-title":"Expert Review of Vaccines"},{"issue":"9-10","key":"10.1016\/j.vaccine.2022.08.001_b0095","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.vaccine.2003.08.047","article-title":"Immunization with meningococcal polysaccharide\u2013tetanus toxoid conjugate induces polysaccharide-reactive T cells in mice","volume":"22","author":"Muthukkumar","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.001_b0100","doi-asserted-by":"crossref","unstructured":"Strikas RA, Centers for Disease C and Prevention (CDC), Advisory Committee on Immunization P (ACIP), ACIP Child\/Adolescent Immunization Work Group. Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years-United States, 2015.MMWR Morb Mortal Wkly Rep 2015 Feb 6;64(4):93-4. https:\/\/doi.org\/ https:\/\/pubmed.ncbi.nlm.nih.gov\/25654610\/.","DOI":"10.1111\/ajt.13293"},{"issue":"17-18","key":"10.1016\/j.vaccine.2022.08.001_b0105","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection?serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.001_b0110","unstructured":"ClinicalTrials.gov. Study of a tetravalent meningococcal diphtheria toxoid conjugate vaccine in toddlers 9 to 18 months of age (NCT00643916);2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00643916."},{"key":"10.1016\/j.vaccine.2022.08.001_b0115","doi-asserted-by":"crossref","unstructured":"Pina LM, Bassily E, Machmer A, Hou V, Reinhardt A. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. Pediatr Infect Dis J 2012 Nov;31(11):1173-83. https:\/\/doi.org\/ 10.1097\/INF.0b013e318268dfe4.","DOI":"10.1097\/INF.0b013e318268dfe4"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.001_b0120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1155\/2014\/237560","article-title":"Safety and immunogenicity of two doses of quadrivalent meningococcal conjugate vaccine or one dose of meningococcal group C conjugate vaccine, both administered concomitantly with routine immunization to 12- to 18-month-old children","volume":"25","author":"Noya","year":"2014","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.vaccine.2022.08.001_b0125","doi-asserted-by":"crossref","unstructured":"Block SL, Shepard J, Garfield H, Xie F, Han L, Dull PM, et al. Immunogenicity and safety of a 3- and 4-dose vaccination series of a meningococcal ACWY conjugate vaccine in infants: results of a phase 3b, randomized, open-label trial. Pediatr Infect Dis J 2016 Feb;35(2):e48-59. https:\/\/doi.org\/ 10.1097\/INF.0000000000000965.","DOI":"10.1097\/INF.0000000000000965"},{"key":"10.1016\/j.vaccine.2022.08.001_b0130","doi-asserted-by":"crossref","unstructured":"Klein NP, Shepard J, Bedell L, Odrljin T, Dull P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine 2012 Jun 6;30(26):3929-36. https:\/\/doi.org\/ 10.1016\/j.vaccine.2012.03.080.","DOI":"10.1016\/j.vaccine.2012.03.080"},{"key":"10.1016\/j.vaccine.2022.08.001_b0135","doi-asserted-by":"crossref","unstructured":"Simon MW, Brandon D, Christensen S, Baccarini C, Jordanov E, Dhingra MS. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered in healthy meningococcal vaccine-naive children (2-9 years). Open Forum Infect Dis 2019 Oct;6(Suppl 2): S958-9. https:\/\/doi.org\/ 10.1093\/ofid\/ofz360.2401.","DOI":"10.1093\/ofid\/ofz360.2401"},{"key":"10.1016\/j.vaccine.2022.08.001_b0140","unstructured":"Shi N, QU Y, AI X, Pang R, Bai Y, Yang L, et al. Safety and immunogenicity of groups A + C meningococcal conjugate vaccine. Chinese Journal of Biologicals 2010;23(8): 878-80 + 84. https:\/\/doi.org\/0.13200\/j.cjb.2010.08.92.shinm.012."},{"key":"10.1016\/j.vaccine.2022.08.001_b0145","unstructured":"Shi L, Liang X, LI H, Fang W, Li Y, Mo Z. Immunogenicity and safety of freeze-dried groups A and C meningococcal polysaccharide con jugate vaccine in healthy infants at ages of 3\u223c8 months. Chinese Journal of Biological 2020;33(3):297-301+307. https:\/\/doi.org\/10.13200\/j.cnki.cjb.003010."},{"key":"10.1016\/j.vaccine.2022.08.001_b0150","unstructured":"Menveo. Package insert. Sovicille, Italy: GlaxoSmithKline Vaccines; 2019. https:\/\/www.fda.gov\/media\/78514\/download."},{"issue":"50","key":"10.1016\/j.vaccine.2022.08.001_b0155","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1016\/j.vaccine.2010.09.092","article-title":"Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2\u201310 years of age","volume":"28","author":"Halperin","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.001_b0160","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4161\/hv.1.6.2301","article-title":"Safety and Immunogenicity of a Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Children Aged 2 to 10 Years in Chile","volume":"1","author":"Lagos","year":"2005","journal-title":"Human Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.001_b0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.inf.0000148928.10057.86","article-title":"Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children","volume":"24","author":"Pichichero","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.08.001_b0170","doi-asserted-by":"crossref","unstructured":"Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 2012 Jan;31(1):64-71. https:\/\/doi.org\/ 10.1097\/INF.0b013e31823dce5c.","DOI":"10.1097\/INF.0b013e31823dce5c"},{"key":"10.1016\/j.vaccine.2022.08.001_b0175","doi-asserted-by":"crossref","unstructured":"Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when coadministered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine 2011 Jun 6; 29 (25): 4274-84. https:\/\/doi.org\/ 10.1016\/j.vaccine.2011.03.043.","DOI":"10.1016\/j.vaccine.2011.03.043"},{"key":"10.1016\/j.vaccine.2022.08.001_b0180","doi-asserted-by":"crossref","unstructured":"Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011 Apr; 30(4): e56-62. https:\/\/doi.org\/ .","DOI":"10.1097\/INF.0b013e31820e6e02"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:21:17Z","timestamp":1759404077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22009483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":36,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0264410X22009483"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.001","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II, single-center, randomized, double-blind, parallel control clinical study evaluating the immunogenicity and safety of a two-dose schedule of serogroups ACYW meningococcal polysaccharide conjugate vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}